Altered cyclooxygenase-1 and enhanced thromboxane receptor activities underlie attenuated endothelial dilatory capacity of omental arteries in obesity.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
15 Dec 2019
Historique:
received: 07 10 2019
revised: 29 10 2019
accepted: 31 10 2019
pubmed: 11 11 2019
medline: 14 2 2020
entrez: 10 11 2019
Statut: ppublish

Résumé

Obesity is a risk factor for endothelial dysfunction, the severity of which is likely to vary depending on extent and impact of adiposity on the vasculature. This study investigates the roles of cyclooxygenase isoforms and thromboxane receptor activities in the differential endothelial dilatory capacities of arteries derived from omental and subcutaneous adipose tissues in obesity. Small arteries were isolated from omental and subcutaneous adipose tissues obtained from consented morbidly obese patients (n = 65, BMI 45 ± 6 kg m Acetylcholine relaxation was significantly attenuated in omental compared with subcutaneous arteries from same patients (p < 0.01). Indomethacin (p < 0.01) and FR122047 (p < 0.001) but not Celecoxib significantly improved the omental arteriolar relaxation. Cyclooxygenase-1 mRNA and U46619 contractions were both increased in omental compared with subcutaneous arteries (p < 0.05). L-NAME comparably inhibited acetylcholine relaxation in both arteries, while apamin+charybdotoxin were less effective in omental compared with subcutaneous arteries. The results show that the depot-specific reduction in endothelial dilatory capacity of omental compared with subcutaneous arteries in obesity is in large part due to altered cyclooxygenase-1 and enhanced thromboxane receptor activities, which cause EDHF deficiency.

Identifiants

pubmed: 31704447
pii: S0024-3205(19)30966-X
doi: 10.1016/j.lfs.2019.117039
pii:
doi:

Substances chimiques

Cyclooxygenase Inhibitors 0
Receptors, Thromboxane 0
Charybdotoxin 115422-61-2
Apamin 24345-16-2
Cyclooxygenase 1 EC 1.14.99.1
Celecoxib JCX84Q7J1L
NG-Nitroarginine Methyl Ester V55S2QJN2X
Indomethacin XXE1CET956

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117039

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Asmaa Raees (A)

Qatar Analytics and BioResearch Lab, Anti-Doping Lab Qatar, Qatar.

Aysha Bakhamis (A)

Qatar Analytics and BioResearch Lab, Anti-Doping Lab Qatar, Qatar.

Vidya Mohamed-Ali (V)

Qatar Analytics and BioResearch Lab, Anti-Doping Lab Qatar, Qatar.

Moataz Bashah (M)

Metabolic and Bariatric Surgery Department, Hamad Medical Corporation, Doha, Qatar.

Mashael Al-Jaber (M)

Qatar Analytics and BioResearch Lab, Anti-Doping Lab Qatar, Qatar.

David Abraham (D)

Centre for Rheumatology and Connective Tissue Diseases, Division of Medicine, University College London, UK.

Lucie H Clapp (LH)

Institute of Cardiovascular Sciences, University College London, UK.

Nelson N Orie (NN)

Qatar Analytics and BioResearch Lab, Anti-Doping Lab Qatar, Qatar. Electronic address: norie@adlqatar.qa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH